Accelerate Development with Lannett CDMO - Streamlined development of oral solid dose formulations - Extensive expertise and high-volume manufacturing - Commitment to quality and regulatory compliance Our track record speaks volumes - 17 approved product applications since 2019 - 96% average product yield rate - Zero critical FDA Form 483 observations Learn More About Partnering with Lannett. https://www.lannettcdmo.com/